

Quarterly Financial Report

Q4 2024 Summary

This document provides an overview of our Q4 2024 performance.

Key highlights include revenue growth, regional expansion, and new product launches.

Executive Summary

Revenue increased by 15% year-over-year, driven by strong performance in the healthcare technology sector. Operating margins improved to 23.5%.

Financial Metrics


Metric	Q3 2024	Q4 2024	Change
Revenue (\$M)	142.3	163.6	+15.0%
Operating Income (\$M)	31.2	38.4	+23.1%
Net Income (\$M)	24.8	29.7	+19.8%
EPS (\$)	1.24	1.49	+20.2%

Regional Performance

North America contributed 65% of total revenue, followed by Europe (25%) and Asia-Pacific (10%). All regions showed positive growth.

Product Highlights

Our flagship product saw 40% adoption increase. Below is our product logo:



Conclusion

Q4 2024 demonstrated strong execution across all business units.

We remain confident in our 2025 outlook with continued investment in R&D.